Post by
fossi_2002 on Mar 08, 2024 3:41am
Why is AEZS trading below the cash value?
Why is AEZS trading below the cash value?
Novo Nordisk returned license for macimorelin in U.S. and
Canada
Sales of Macrilen ® for adult use in U.S. temporarily
discontinued as of May 23, 2023
Robust business development
efforts to identify and secure a
commercialization partner
Strong cash position with cash projected to fund operations and advancement of priority pipeline programs into 2025 (based on management´s current expectations and planned development avtivities)
Why does it take so long to find a new partner for the US market?
When AEZS runs out of money in 2025, it should be clear to everyone why they need Ceapro's pipeline.
No matter how much Proph writes about possible milestone payments.
This data does not come from the future, but from the current presentation by AEZS itself.
On a positive note, shareholders are kept up to date on the homepage.
At Ceapro, for example, the presentation page has been referring to the following for months: coming soon - the only question is: when is soon?
Comment by
lscfa on Mar 08, 2024 9:58am
"Why does it take so long to find a new partner for the US market?" AEZS wants to do a single license of Macimorelin for adult and child use so waiting for child clinical results.